About Brattea
Brattea is a Healthcare company based in Xuhui (China) founded in 2013 by Hongguang Cao. Brattea has raised $15.2 million across 3 funding rounds from investors including Zhongping Capital, Shanghai Healthcare Capital and Shenzhen Dingxin Capital Management. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices.
Company details
Developer of a medical device for the treatment of hypertension. The product is a Renal artery radiofrequency ablation instrument, a minimally invasive way to deliver the catheter into the renal artery, that performs radiofrequency ablation of the renal artery sympathetic nerve and blocks the sympathetic nerve to treat hypertension and chronic kidney disease hypertension. This device has a mesh basket structure and 6 electrodes. The company also works in the field of tumor analgesia, diabetes, vasculitis, and heart disease.
- Headquarters Xuhui, China
- Founders Hongguang Cao
- SectorsHealthcare
- Website brattea.com
- Total Equity Funding$15.2M (USD)
in 3 rounds
- InvestorsZhongping Capital
& 8 more
Funding Insights of Brattea
Brattea has successfully raised a total of $15.2M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.2M
- Total Rounds 3
- First Round $15.2M
(Apr 2021)
- Investors Count 9
All 3 funding rounds of Brattea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | Series D | – | Zhongping Capital | ||
| Dec 2022 | Series C | – | Fosunhealth | ||
| Apr 2021 | $15.2M | Series B | – | Kuanping Capital |
9 investors in total: 9 institutional.
Investors in Brattea
Brattea has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Zhongping Capital, Shanghai Healthcare Capital and Shenzhen Dingxin Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| zhongpingcapital.com | ||||
| siicshc.com | ||||
Venture capital firm investing in series A startups | dingxin-capital.com | Shenzhen, China | ||
| nnfe.com.cn | ||||
Hengxu Capital is recognized as a market-oriented investment institution. | 2019 | hengxucapital.com | Shanghai, China | |
| kuanping-capital.com | ||||
| saiccapital.com | ||||
| spinnotec.com | ||||
| fosunhealth.com |
Investor details for Brattea
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Brattea
1 people are tracked at Brattea (1 in leadership).
| Name | Role | Group |
|---|---|---|
Hongguang Cao | Founder | Leadership |
Complete people profiles for Brattea
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Brattea
3 dated milestones of Brattea across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Brattea is founded.
- Funding First funding round of $15.2M.
- Funding Latest funding round, Series D,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brattea
Complete news archive for Brattea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Brattea
Brattea was founded in 2013 and raised its 1st funding round 8 years after it was founded.
Brattea is headquartered in Xuhui, China. It is registered at Xuhui, Shanghai, China.
Brattea is a funded company, having raised a total of $15.2M across 3 funding rounds to date. The company's 1st funding round was a Series B of $15.2M, raised on Apr 2021.
Developer of a medical device for the treatment of hypertension. The product is a Renal artery radiofrequency ablation instrument, a minimally invasive way to deliver the catheter into the renal artery, that performs radiofrequency ablation of the renal artery sympathetic nerve and blocks the sympathetic nerve to treat hypertension and chronic kidney disease hypertension. This device has a mesh basket structure and 6 electrodes. The company also works in the field of tumor analgesia, diabetes, vasculitis, and heart disease.
Brattea has 9 investors. Key investors include Zhongping Capital, Shanghai Healthcare Capital, Shenzhen Dingxin Capital Management, Fosunhealth, and NNFE.